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Case Report
Introduction
Acute fibrinous and organizing pneumonia (AFOP) is an 
extremely rare diffuse parenchymal lung disease that was 
first described by Beasley et al1 as a possible variant of dif-
fuse alveolar damage (DAD), bronchiolitis obliterans with 
organizing pneumonia (BOOP), or eosinophilic pneumonia 
(EP). It is now understood to be a distinct form of lung 
injury that is characterized pathologically by the presence 
of intra-alveolar fibrin and organizing pneumonia in a 
patchy distribution. AFOP has been observed in patients 
with collagen vascular disease, various infections, occupa-
tional exposures, or adverse drug reactions,1,2 making it dif-
ficult to identify clinical characteristics that are specific to 
AFOP. Here we report the first case series of 2 patients who 
developed AFOP following allogenic hematopoietic stem 
cell transplant (HSCT), which suggests AFOP may be more 
common in this patient group than previously recognized.
Case Report
Patient 1
A 39-year-old Caucasian man with acute B-cell lymphoblas-
tic leukemia presented 6 weeks after allogenic HSCT. He 
presented with 1 week of cough and fevers with stable vital 
signs and an oxygen saturation of 96% on room air. 
Pulmonary exam was notable for faint crackles at the right 
apex. Laboratory studies revealed a normal white blood cell 
(WBC) count and differential. Chest X-ray and chest 
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Abstract
Acute fibrinous and organizing pneumonia (AFOP) is an extremely rare, relatively new, and distinct histological pattern of 
acute lung injury characterized predominately by the presence of intra-alveolar fibrin and associated organizing pneumonia. 
AFOP may be idiopathic or associated with a wide spectrum of clinical conditions. It has a variable clinical presentation from 
mild respiratory symptoms to that similar to the acute respiratory distress syndrome. Currently there is no consensus on 
treatment, and corticosteroids previously were of unclear benefit. To date, there are less than 40 cases of AFOP reported in 
the literature and only one has been linked to hematopoietic stem cell transplantation. Here we report the first case series 
of 2 patients who developed AFOP following allogenic stem cell transplant that were successfully treated with high-dose 
corticosteroids.
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computed tomography (CT) scan demonstrated bilateral air-
space opacities (Figures 1-3).
Bronchoscopy with bronchoalveolar lavage (BAL) of 
the right upper lobe and transbronchial biopsy of the right 
lower lobe were performed on hospital day 2. BAL cell 
count showed 605 WBC/mL with 76% histiocytes, 19% 
polymorphonuclear leukocytes, and 6% lymphocytes. 
Bacterial, fungal, viral, and acid fast bacilli studies from 
BAL were all negative. Transbronchial biopsy was nondi-
agnostic. All other extensive infectious workup was 
unremarkable.
Despite administration of broad-spectrum antibiotics and 
antifungals, the patient had worsening cough, dyspnea, and 
progressive hypoxemia, and therefore underwent surgical 
lung biopsy on hospital day 9 with pathology consistent with 
AFOP (Figure 4).
Patient 2
A 25-year-old Hispanic man presented 25 days after allo-
genic HSCT for relapsed B-cell lymphoma with persistent 
fevers of 102°F, progressive dyspnea, and cough. His chest 
imaging demonstrated multifocal pulmonary nodules, as 
seen in Figures 5 and 6.
He underwent bronchoscopy with BAL of the left lower 
lobe; WBC count was 970/mL (4% polymorphonuclear cells, 
41% lymphocytes, 38% histiocytes, and 17% macrophages). 
Bacterial, fungal, viral, and acid-fast bacilli cultures from 
BAL were all negative. The patient underwent a surgical 
biopsy on hospital day 21. Pathologic examination revealed 
diffuse AFOP as well as an acute and organizing stage of dif-
fuse alveolar damage (Figure 7). Following surgical lung 
biopsy, the patient developed the acute respiratory distress 
syndrome (ARDS) requiring ventilatory support.
Both patients were started on corticosteroids at 1 mg/kg 
of prednisone equivalence with clinical and radiographic 
response (Figure 6). After more than 6 months, both patients 
had full resolution of their pulmonary symptoms and were 
maintained on minimal prednisone doses (<5 mg daily).
Discussion
AFOP is an extremely rare pathologic entity with unclear eti-
ology, vague clinical presentation, and no consensus treat-
ment with potential deadly consequence. This spectrum of 
disease currently does not fit within the definition of ideo-
pathic interstital pneumonias based on the American Thoracic 
Society and European guidelines.3 To make it more confus-
ing, most reported cases of AFOP have no identifiable risk 
factors, and the diagnosis of AFOP is similar to other forms 
of acute lung injury, often mimicking developing ARDS. Of 
the 17 cases of AFOP reviewed by Beasley et al, 6 cases had 
no identifiable association while the other 11 cases were 
believed to be associated with collagen vascular disease (3), 
amiodarone (1), Haemophilus influenza (1), Acinetobacter 
sp (1), lymphoma (1), and occupational exposures (including 
hairspay, coal mining, construction work, and zoological 
work1). Subsequent case reports since Beasley et al publica-
tion have linked AFOP to H1N1 infection, undiffentiated 
connective tissue diseases, bone marrow transplant, and 
others.4,5,6,7 Symptoms are nonspecific and include fever, 
cough, and dyspnea. Radiographic findings include bilateral dif-
fuse migratory alveolar opacities distributed peripherally.1,2,7,8 
There are 2 reported patterns of disease progression: a fulmi-
nant illness with overlapping features of ARDS which car-
ries a much higher mortality and a more subacute illness with 
spontaneous recovery.1,9
Histologically, the AFOP pattern can be difficult to distin-
guish from other acute lung injury patterns of DAD, OP, or 
EP, especially on smaller biopsy specimens. Intra-alveolar 
fibrin, a dominant finding in the AFOP pattern, can also be 
seen in DAD, OP, and EP. AFOP pattern differs from DAD, 
OP, and EP by the presence of prominent organizing intra-
alveolar fibrin, the lack of hyaline membrane, and rare num-
bers of eosinophils. A surgical biopsy is recommended for a 
diagnosis of the AFOP pattern. The key features of AFOP, 
DAD, COP, and EP patterns are summarized in Table 1.1,10
Currently, there are no established guidelines for the treat-
ment of AFOP. Compared to OP, AFOP responds less reli-
ably to steroids and portends a higher mortality rate. Among 
the 17 patients in the Beasley et al1 study, 7 patients received 
corticosteroids but only one survived. Other immune-modu-
lators, such as cyclophosphamide, azathioprine, and myco-
phenolate mofetil, have been used in combination with 
corticosteroids in individual case reports with varying 
degrees of success.11 ARDS and respiratory failure requiring 
Figure 1. Admission imaging. Chest X-ray with evidence of 
bilateral airspace opacities.
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mechanical ventilation was primarily a predictor of poor out-
come in the majority of case reports.1,6 In contrast to the 
other reported cases of AFOP following HSCT who pro-
gressed and died, our patients had excellent clinical responses 
to corticosteroids. Both patients presented with a subacute to 
acute illness, with patient 2 progressing to respiratory failure 
and ARDS requiring mechanical ventilatory support. 
However, despite having clinical features of ARDS, patient 2 
Figure 2. Admission chest CT. (a) Apical 1.25 mm cut showing widespread multifocal patchy opacities, most prominent at the apices. 
(b) Bibasilar with scattered opacities.
Figure 3. Comparative chest CTs. Admission CT scan (left; [a] upper lung zone, [c] lower lung zones). CT scan 9 days later (right; [b] 
upper lung zone, [d] lower lung zone) with worsening bilateral patchy and confluent airspace opacities.
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was quickly liberated from mechanical ventilation. The use 
of corticosteroids in ARDS has been controversial and poten-
tially harmful when given late in the course (>14 days), 
though our patient with AFOP had an excellent clinical 
response to high-dose steroids. Whether the underlying 
pathophysiology of AFOP makes patients more responsive 
to corticosteroids versus patients with infection-associated 
ARDS is unclear.
We believe that early diagnosis with prompt initiation of 
corticosteroid therapy may explain the excellent clinical 
responses in these AFOP cases. Also, early surgical lung 
biopsy should be considered in ARDS cases following HSCT 
who develop unexplained pulmonary infiltrates with poor 
response to empiric antimicrobial therapy. A biopsy to deter-
mine if they have AFOP, a condition likely amenable to ste-
roid therapy, may change the course of treatment.
Conclusion
AFOP is a rare, relatively new, and distinct histological pat-
tern of acute lung injury with variable presentation and a 
high mortality. Early recognition and prompt diagnosis is 
essential, including consideration of surgical lung biopsy. 
Treatment with steroids should be considered, despite 
patients presenting with ARDS, if the underlying histologi-
cal pattern is that of AFOP. To our knowledge, we report the 
first case series of AFOP presenting with hypoxic respiratory 
insuffiency progressing to ARDS following HSCT success-
fully treated with steroids.
Figure 4. Histopathology of Patient 1. (a) Low magnification showing patchy, nodular intraluminal involvement. (b) Prominent fibrinous 
exudate in peribronchiolar parenchyma. (c) Higher magnification showing the fibrinous exudate within alveolar spaces. (d) Focally 
associated with organization.
Figure 5. Admission chest X-ray of Patient 2. Bilateral nodular 
densities, most prominent in the periphery.
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Figure 6. Radiographic comparison before and after corticosteroid therapy. Admission CT scan (left; [a] upper lung zone, [c] middle 
lung zone, [e] lower lung zone). Two months after high-dose corticosteroid therapy with marked improvement (right; [b] upper lung 
zone, [d] middle lung zone, [f] lower lung zones).
Figure 7. Histopathology of Patient 2. Biopsy results of right upper, middle, and lower lobes reveal diffuse acute fibrinous and 
organizing pneumonia (a) as well as an acute and organizing stage of diffuse alveolar damage (b).
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Table 1. Histologic Features of AFOP and Other Acute Lung Injury Patterns.
Predominant Histologic Distinction AFOP DAD OP EP
Intra-alveolar fibrin deposition Yes, prominent +/−, focal +/−, focal Yes, prominent
Intra-alveolar fibroblastic plugs (Masson bodies) No No Yes, prominent +/−, focal
Hyaline membranes No Yes, extensive No +/−, focal
Eosinophils parenchymal infiltrates Rare Rare Rare Yes, extensive
Abbreviations: AFOP, acute fibrinous and organizing pneumonia; DAD, diffuse alveolar damage; OP, organizing pneumonia; EP, eosinophilic pneumonia.
